Literature DB >> 30120594

Association of HER2 gene amplification and tumor progression in early gastric cancer.

Kazuki Kanayama1,2, Hiroshi Imai3, Eri Usugi2, Taizo Shiraishi2,4, Yoshifumi S Hirokawa2, Masatoshi Watanabe2.   

Abstract

Overexpression of human epidermal growth factor receptor 2 (HER2) protein in association with HER2 gene amplification is found in 7-34% of gastric cancers. In breast cancer, HER2 overexpression is a prognostic factor in advanced cases and is associated with tumor progression in ductal carcinoma in situ. However, the biological and clinical significance of HER2 status in early gastric cancer is unknown. Here, we aimed to examine the correlation between HER2 gene amplification and tumor progression in early gastric cancer. The HER2 status was evaluated in 149 lesions from 141 consecutive patients with early gastric cancer who underwent endoscopic resection by immunohistochemistry and dual color in situ hybridization. HER2 gene amplification was detected in 35 (23.5%) of 149 lesions, and of those, 26 cases (74.3%) showed intratumoral heterogeneity. HER2 gene amplification was found in noninvasive carcinoma, and there was a significant correlation between HER2 status and T factor (P = 0.0290). Our study demonstrated that HER2 gene amplification occurred during the early stages of gastric cancer and showed heterogeneity in several cases. HER2 gene amplification may be involved in tumor progression in early gastric cancer.

Entities:  

Keywords:  Early gastric cancer; HER2 gene amplification; HER2 heterogeneity; HER2 homogeneity; Tumor progression

Mesh:

Substances:

Year:  2018        PMID: 30120594     DOI: 10.1007/s00428-018-2433-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  25 in total

1.  Lesions indefinite for intraepithelial neoplasia and OLGA staging for gastric atrophy.

Authors:  Matteo Fassan; Marco Pizzi; Fabio Farinati; Donato Nitti; Vittorina Zagonel; Robert M Genta; Massimo Rugge
Journal:  Am J Clin Pathol       Date:  2012-05       Impact factor: 2.493

2.  Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study.

Authors:  M Rugge; M de Boni; G Pennelli; M de Bona; L Giacomelli; M Fassan; D Basso; M Plebani; D Y Graham
Journal:  Aliment Pharmacol Ther       Date:  2010-02-23       Impact factor: 8.171

3.  Gastritis: the histology report.

Authors:  Massimo Rugge; Gianmaria Pennelli; Emanuela Pilozzi; Matteo Fassan; Giuseppe Ingravallo; Valentina M Russo; Francesco Di Mario
Journal:  Dig Liver Dis       Date:  2011-03       Impact factor: 4.088

4.  The Vienna classification of gastrointestinal epithelial neoplasia.

Authors:  R J Schlemper; R H Riddell; Y Kato; F Borchard; H S Cooper; S M Dawsey; M F Dixon; C M Fenoglio-Preiser; J F Fléjou; K Geboes; T Hattori; T Hirota; M Itabashi; M Iwafuchi; A Iwashita; Y I Kim; T Kirchner; M Klimpfinger; M Koike; G Y Lauwers; K J Lewin; G Oberhuber; F Offner; A B Price; C A Rubio; M Shimizu; T Shimoda; P Sipponen; E Solcia; M Stolte; H Watanabe; H Yamabe
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

5.  HER2 expression and its clinicopathological features in resectable gastric cancer.

Authors:  Yoshiki Kataoka; Hiroshi Okabe; Akihiko Yoshizawa; Sachiko Minamiguchi; Kenichi Yoshimura; Hironori Haga; Yoshiharu Sakai
Journal:  Gastric Cancer       Date:  2012-03-14       Impact factor: 7.370

6.  Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype.

Authors:  Mauro Cassaro; Massimo Rugge; Chiara Tieppo; Luciano Giacomelli; Daniela Velo; Donato Nitti; Fabio Farinati
Journal:  J Clin Pathol       Date:  2007-06       Impact factor: 3.411

7.  Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.

Authors:  J Bartkova; D M Barnes; R R Millis; W J Gullick
Journal:  Hum Pathol       Date:  1990-11       Impact factor: 3.466

8.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.

Authors:  Luis A Diaz; Richard T Williams; Jian Wu; Isaac Kinde; J Randolph Hecht; Jordan Berlin; Benjamin Allen; Ivana Bozic; Johannes G Reiter; Martin A Nowak; Kenneth W Kinzler; Kelly S Oliner; Bert Vogelstein
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

9.  Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.

Authors:  Akira Sawaki; Yasuo Ohashi; Yasushi Omuro; Taroh Satoh; Yasuo Hamamoto; Narikazu Boku; Yoshinori Miyata; Hiroya Takiuchi; Kensei Yamaguchi; Yasutsuna Sasaki; Tomohiro Nishina; Atsushi Satoh; Eishi Baba; Takao Tamura; Takashi Abe; Kiyohiko Hatake; Atsushi Ohtsu
Journal:  Gastric Cancer       Date:  2011-12-17       Impact factor: 7.370

10.  A Big Bang model of human colorectal tumor growth.

Authors:  Andrea Sottoriva; Haeyoun Kang; Zhicheng Ma; Trevor A Graham; Matthew P Salomon; Junsong Zhao; Paul Marjoram; Kimberly Siegmund; Michael F Press; Darryl Shibata; Christina Curtis
Journal:  Nat Genet       Date:  2015-02-09       Impact factor: 38.330

View more
  14 in total

1.  Intratumoral HER2 heterogeneity in early gastric carcinomas: potential bias in therapeutic management.

Authors:  Antonio Ieni; Roberta Cardia; Maria Lentini; Giovanni Tuccari
Journal:  Virchows Arch       Date:  2018-11-30       Impact factor: 4.064

2.  Letter to the editor: reply to Antonio Ieni "Intratumoral HER2 heterogeneity in early gastric carcinomas: potential bias in therapeutical management".

Authors:  Kazuki Kanayama; Hiroshi Imai; Eri Usugi; Taizo Shiraishi; Yoshifumi S Hirokawa; Masatoshi Watanabe
Journal:  Virchows Arch       Date:  2019-01-19       Impact factor: 4.064

3.  Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study.

Authors:  Katharina Kolbe; Ivonne Haffner; Katrin Schierle; Dieter Maier; Birgitta Geier; Birgit Luber; Hendrik Bläker; Christian Wittekind; Florian Lordick
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-27       Impact factor: 4.322

4.  Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.

Authors:  Pengfei Yu; Yusheng Wang; Yanfei Yu; Aodi Wang; Ling Huang; Yuan Zhang; Wenjing Liu; Haiyan Wu; Ming Yao; Yi-An Du; Xiangdong Cheng
Journal:  Oncologist       Date:  2021-02-08

5.  Comparative effectiveness and tolerability of targeted agents combined with chemotherapy in patients with HER2-positive gastroesophageal cancer: A network meta-analysis.

Authors:  Yin-Hong Yan; Xiao-Yi Lei; Wei-Ping Hu
Journal:  Saudi J Gastroenterol       Date:  2022 May-Jun       Impact factor: 3.214

6.  Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer.

Authors:  Wenying Yan; Hongmei Hu; Biao Tang
Journal:  Onco Targets Ther       Date:  2019-09-30       Impact factor: 4.147

7.  Heart Failure and Malignancy: Implications of Chemotherapy and Radiation in the Pathogenesis of Cardiomyopathy in Cancer Treated Populations.

Authors:  Perry Wengrofsky; Maya Srinivasan; Haytham Aboushi; Vaibhavi Solanki; Inna Bukharovich; Fadi Yacoub; Maria Poplawska; Samy I McFarlane
Journal:  J Cardiol Cardiovasc Ther       Date:  2020-12-18

8.  Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 Registry.

Authors:  Florian Huemer; Lukas Weiss; Peter Regitnig; Thomas Winder; Bernd Hartmann; Josef Thaler; Gudrun Piringer; Clemens A Schmitt; Wolfgang Eisterer; Hannes Gänzer; Alois Wüstner; Johannes Andel; Björn Jagdt; Hanno Ulmer; Richard Greil; Ewald Wöll
Journal:  J Clin Med       Date:  2020-03-29       Impact factor: 4.241

Review 9.  Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer.

Authors:  Alessandro Cavaliere; Valeria Merz; Simona Casalino; Camilla Zecchetto; Francesca Simionato; Hayley Louise Salt; Serena Contarelli; Raffaela Santoro; Davide Melisi
Journal:  J Gastric Cancer       Date:  2019-11-13       Impact factor: 3.720

10.  Evaluation of Near-infrared Fluorescence-conjugated Peptides for Visualization of Human Epidermal Receptor 2-overexpressed Gastric Cancer.

Authors:  Kyoungyun Jeong; Seong-Ho Kong; Seong-Woo Bae; Cho Rong Park; Felix Berlth; Jae Hwan Shin; Yun-Sang Lee; Hyewon Youn; Eunhee Koo; Yun-Suhk Suh; Do Joong Park; Hyuk-Joon Lee; Han-Kwang Yang
Journal:  J Gastric Cancer       Date:  2021-06-28       Impact factor: 3.720

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.